anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators propose to address the influence of ellagic acid obtained from walnuts and its microbial-derived metabolites (urolithin) on the gut microbiome and inflammation-related biomarkers in a human clinical study. Patients will be enrolled and detailed demographic and dietary information, biopsy specimens through colonoscopies, as well as fecal, blood and urine samples will be collected. The wide range of gut urolithin levels provides the rationale for our proposed studies. Will the specific urolithin phenotypes show a disparate range of chemopreventive (anti-inflammatory) response to walnut consumption? The hypothesis is that walnut ingestion in "Phenotype A" participants (producing the highest levels of urolithin) will be associated with a beneficial anti-inflammatory response as tested in colonic mucosa and a higher abundance of bacterial species associated with ellagic acid metabolism. Although 16S ribosomal ribonucleic acid gene (rRNA) sequencing allows inexpensive bacterial identification at the genus/species level, a whole genome sequencing (mWGS) will be employed to achieve finer classification (strain level), and identify other microbes (e.g., viruses, fungi, small eukaryotes). Furthermore, mWGS targets the entire genome of each microbe (not just the 16S rRNA gene), allowing for construction of a microbial gene catalogue, including a metabolic pathway description for each sample. This will characterize the functional potential of the microbial community. Ultimately, the proposed studies will inform the application of prebiotic to enhance the formation of urolithin metabolites from ellagic acid for the prevention of inflammation-associated Colorectal Cancer, a development that would have significant translational implications.
Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
A system for generating a comestible plan to manage musculoskeletal system disorders is disclosed. The system comprises a computing device configured to receive an input comprising physiological data. Computing device may generate a physiological data classifier, Computing device may classify, using the physiological data classifier, the physiological data to a class of physiological data relating to musculoskeletal disorders. Computing device may extract a plurality of biological determinants of a disease state from the physiological data, wherein the plurality of biological determinants includes at least one biological determinant related to at least one disorder located in musculoskeletal system. Computing device may determine a biological determinant concentration. Computing device may identify a musculoskeletal system disorder based on the at least one biological determinant and the biological determinant concentration. Computing device may generate a holistic program as a function of a positive result for the musculoskeletal system disorder.
PURPOSE:To provide a novel soft capsule agent having uniform content of the active component, remarkably improved dissolution rate of the drug, and excellent appearance, by coating an oily substance with a skin component containing a water-soluble drug. CONSTITUTION:The novel soft capsule agent is prepared by coating an oily substance with a skin component (e.g. gelatin) containing a water-soluble drug. The water-soluble drug is not restricted to the one completely soluble in water, and a drug which can be solubilized by the addition of a dissolution assistant, etc. may be used. The skin component may contain colorant, plasticizer, antiseptic, antioxidant, etc. Any oily substance used as a content of conventional soft capsule agent, e.g. olive oil, sesame oil, tricaprylic acid glyceride, etc. may be used as the oily component of the present agent, and it may contain a drug other than the drug in the skin component. When both oily substance and the skin are transparent, the obtained soft capsule has excellent appearance.
A method of synthesizing and purifying a high molecular weight aggregate, derived from hematoporphyrin, said material being useful in the localization and treatment of tumors. The substance results from the hydrolysis of the reaction mixture of hematoporphyrin and acetic-sulfuric acids. The material is purified by cycling the crude product through a micro-porous membrane system in which exclusion of low molecular weight by-products is effected. The substance is tumor-selective and photosensitizing. It is retained in tumors longer than in normal tissues and fluoresces red to aid in diagnosis. Strong illumination of tumors retaining the substance results in necrosis, while normal tissues which have generally eliminated the drug remain unaffected. The high molecular weight aggregate has an empirical formula of approximately C68H70N8O11 (Na plus H)4.
Mendelian Randomization studies indicate that BMI contributes to various diseases, but it's unclear if this is entirely mediated by BMI itself. This study examines whether disease risk from BMI-associated sequence variants is mediated through BMI or other mechanisms, using data from Iceland and the UK Biobank. The associations of BMI genetic risk score with diseases like fatty liver disease, knee replacement, and glucose intolerance were fully attenuated when conditioned on BMI, and largely for type 2 diabetes, heart failure, myocardial infarction, atrial fibrillation, and hip replacement. Similar attenuation was observed for chronic kidney disease and stroke, though results varied. Findings were consistent across sexes, except for myocardial infarction. Residual effects may result from temporal BMI changes, pleiotropy, measurement error, non-linear relationships, non-collapsibility, or confounding. The attenuation extent of BMI genetic risk score on disease associations suggests the potential impact of reducing BMI on disease risk.
INTRODUCTION: Kidney transplantation significantly improves the lives of those with end-stage kidney disease, offering best alternative to dialysis. However, transplant success is threatened by the acute and chronic rejection mechanisms due to complex immune responses against the new organ.
AREAS COVERED: The ongoing research into biomarkers holds promise for revolutionizing the early detection and monitoring of the graft health. Liquid biopsy techniques offer a new avenue, with several diagnostic, predictive, and prognostic biomarkers showing promise in detecting and monitoring kidney diseases and an early and chronic allograft rejection.
EXPERT OPINION: Evaluating the protein composition related to kidney transplant results could lead to identifying biomarkers that provide insights into the graft functionality. Non-invasive proteomic biomarkers can drastically enhance clinical outcomes and change the way how kidney transplants are evaluated for patients and physicians if they succeed in this transition. Hence, the advancement in proteomic technologies, leads toward a significant improvement in understanding of the protein markers and molecular mechanisms linked to the outcomes of kidney transplants. However, the road from discovery to the use of such proteins in clinical practice is long, with a need for continuous validation and beyond the singular research team with comprehensive infrastructure and across research groups collaboration.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology and radionuclide diagnostics, and can be used for radionuclide diagnostics of secondary edematous-infiltrative form of breast cancer with Her2/neu overexpression using recombinant address molecules DARPin9_29. Injection form of the radiopharmaceutical is introduced on the basis of technetium-99m labeled recombinant address molecules DARPin9_29, which is prepared immediately before administration. For this purpose in aseptic conditions 1 ml of eluateTcO7 GBq by means of syringe is added to set for preparation of tricarbonyl technetium and incubated at temperature 100 °C for 30 minutes. After incubation, 1,000 mcl of technetium tricarbonyl is added to 334 mcl of DARPin9_29 at a concentration of the basic substance solution of 3.6 mg/l and incubated at temperature of 40 °C for 60 minutes. Further, the obtained compound is purified from protein impurities and non-technetium-bound DARPin9_29 molecules by means of cleaning columns. Preparation produced after cleansing in dose of 500 MBK is diluted in 10 ml of normal saline and slowly introduced into the patient through a sterilizing filter. In 4 hours after administration of the preparation, a single-photon emission computed tomography is performed on a two-detector gamma camera. Obtained results are evaluated and the malignant tumor is diagnosed when visualizing the RFP fixation in the mammary gland tissues.EFFECT: higher specificity and informativity and availability of a diagnostic technique for a secondary edematous-infiltrative form of breast cancer with Her2/neu overexpression.1 cl, 1 dwg, 1 ex
Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
The study will be conducted with patients who will undergo elective surgery and caudal block will be applied between 05.07.2023-05.09.2023 in the Anesthesiology and Reanimation Clinic of Prof. Dr. Cemil Taşçıoğlu City Hospital after Ethics Committee approval and written and verbal consent of the patients. Our prospective observational study will include patients between the ages of 1-7 years, ASA 1-2, who will undergo elective surgery under general anesthesia, whose consent was obtained by their parents for the procedure to be performed. Gender, age, weight, height, body mass index (BMI), ASA (American Society of Anesthesiology) score and medical history of the patients will be recorded. Injection times of pediatric patients who underwent caudal block with 0.125% bupivacaine at a dose of 0.8 ml/kg using a 22 gauge caudal needle will be noted. Optic nerve sheath diameter of the patients will be measured and recorded. Intraoperative hemodynamic parameters, postoperative complications (nausea, vomiting, urinary retention) will also be noted.
Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
Depression with co-morbid alcohol dependence is very prevalent and it is very costly to treat. The co occurrence of the two disorders leads to greater severity and worse long-term outcome, including suicide. Although a number of treatment strategies have been implemented for depressed patients with alcohol dependence the controversy concerning best treatment options for those patients persists.

The clinical relationship between depression and alcohol dependence suggests some common mechanism underlying both disorders. It has been hypothesized that medications that block presynaptic nAChR may be effective in the treatment of alcoholism and depression. Mecamylamine (Inversine ®) is a noncompetitive, high affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Mecamylamine has never been investigated as an effective adjunct treatment for dually diagnosed patients with depression and alcohol dependence. Methods: Thirty participants with a current diagnosis of depression and alcohol dependence will be recruited for this 12-week treatment study. Fifteen participants will be randomized to mecamylamine and fifteen to placebo. Participants will be included in the study if: they meet current DSM-IV criteria for Major Depression and Alcohol Dependence and have been on a stable SSRI dose for 2 weeks. All participants will come weekly to take their medications and complete weekly assessments. Weekly assessments will consist of questioners that will assess depressive symptoms and alcohol consumption over the entire treatment period. Significance: This study is the first to evaluate the efficacy of mecamylamine as an augmenting agent for treatment of depression and alcohol dependence.
A pilot study in which semi-structured interviews will be conducted (Qualitative research).In addition, patients will be asked to fill in a questionnaire about the usability of the prototype. A small group of patients (n=15) that have been treated for early stage NSCLC in the past will be asked to participate. The persons involved in this pilot are asked to assess a patient decision tool and will be interviewed only once. After the interview they will be asked to fill in a questionnaire. The burden of the pilot study is very low. No medical examinations or procedures will be carried out. Pilot study in lung cancer patients treated in the past with radiotherapy or surgery. The participants will all give informed consent. The investigators are using a qualitative design. Semi-structured interviews will be carried out. In addition the investigators will ask the participants to fill in a questionnaire with 35 questions.

No age limits are defined. The pilot study will be carried out in stage I-II NSCLC patients who were treated with radiotherapy or surgery, at least 6 months ago. Patients should currently be free of disease, no disease progression. The semi-structured interview consists of 17 open questions and text recorded, in order to be able to analyze the date afterwards. The interviews will take place when the patients come to the hospital for a regular follow-up appointment. After the interview, the patient is asked to fill in a questionnaire about the usability of the decision aid. In total, the expected duration is about 2 hours.
The goal of this study is to perform a double-blind, placebo-controlled study to investigate the efficacy of cannabis, compared to placebo, in medically ill participants seeking relief symptoms such as pain, nausea, and vomiting. Participants who meet criteria for severe conditions will be referred from their clinicians . Cannabis that has a high concentration of cannabidiol, which is a cannabinoid that does not change perception or produce intoxication, and low in Δ-9-THC will be used. In this way, the hope is to maximize the benefit of cannabis, while lowering the possible side effects of cannabis in medically ill participants.

The overall goal of this study is to compare active high cannabidiol (CBD)/ low (-)-trans-Δ9- tetrahydrocannabinol (THC) cannabis vs placebo cannabis in patients with serious medical disorders. Participants will be referred from clinicians and will come to the laboratory daily (3-5 times weekly) for cannabis (15.76% CBD; 3.11% Δ-9-THC) vs placebo (0.0% CBD/ 0.01% Δ-9-THC). The cannabis will be vaporized or smoked as a cannabis cigarette. The participants can choose which option they prefer. The cross-over design will be used where participants receive 2 weeks of active cannabis vs two weeks of placebo in counterbalanced order, with participants blinded to the condition. The outcome measures primarily include measures of pain, with secondary measures of mood, nausea/appetite, quality of life, and the both the potentially positive and negative subjective effects of cannabis (e.g., high, mellow, anxious, paranoid).
Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 IU/Week) administered during the week preceding the switch to the study drug.
NEW MATERIAL:The benzoylurea compound of formula I (X is Br or Cl). EXAMPLE:N-( 2-nitrobenzoyl )-N-[4-( 5-bromo-2-pyrimidinyloxy )-3-fluorophe nyl]urea. USE:Useful as a carcinostatic agent. It is administered preferably by oral administration. It can be easily administered and is effective at a reduced dose. The pain of patient in administration and the side effect of medicine can be decreased. PREPARATION:The compound of formula I can be produced by reacting the compound of formula II (R1 is isocyanate group or amino group) with the compound of formula III (R2 is amino group or isocyanate group different from R1) in a solvent such as octane, benzene, etc.
Participant allocated to RC will not be exposed to a program, but will be offered 120-minutes of weekly respite care. Caregivers will be asked to record how they spend respite hours each week.
OBJECTIVES: Sex differences occur in atrial fibrillation (AF), including age at first manifestation, pathophysiology, treatment allocation, complication rates and quality of life. However, optimal doses of cardiovascular pharmacotherapy used in women with AF with or without heart failure (HF) are unclear. We investigated sex-specific associations of beta-blocker and renin-angiotensin system (RAS) inhibitor doses with cardiovascular outcomes in patients with AF or AF with concomitant HF.
METHODS: We used data from the prospective Basel Atrial Fibrillation and Swiss Atrial Fibrillation cohorts on patients with AF. The outcome was major adverse cardiovascular events (MACEs), including death, myocardial infarction, stroke, systemic embolisation and HF-related hospitalisation. Predictors of interest were spline (primary analysis) or quartiles (secondary analysis) of beta-blocker or RAS inhibitor dose in per cent of the maximum dose (reference), in interaction with sex. Cox models were adjusted for demographics, comorbidities and comedication.
RESULTS: Among 3961 patients (28% women), MACEs occurred in 1113 (28%) patients over a 5-year median follow-up. Distributions of RAS inhibitor and beta-blocker doses were similar in women and men. Cox models revealed no association between beta-blocker dose or RAS inhibitor dose and MACE. In a subgroup of patients with AF and HF, the lowest hazard of MACE was observed in women prescribed 100% of the RAS inhibitor dose. However, there was no association between RAS dose quartiles and MACE.
CONCLUSIONS: In this study of patients with AF, doses of beta-blockers and RAS inhibitors did not differ by sex and were not associated with MACE overall.
The invention relates to medicinal liquor and especially relates to abdomen stasis-expelling liquor. The abdomen stasis-expelling liquor comprises following components, by weight, 6-18 parts of fennel, 15-19 parts of dried ginger, 5-14 parts of trogopterus dung, 15-20 parts of typhae pollen, 10-15 parts of corydalis yanhusuo, 20-23 parts of angelica sinensis, 25-30 parts of rhizome chuanxiong, 20-30 parts of red peony roots, 5-10 parts of myrrh and 1500-2000 ml of 45-degree liquor, The stasis-expelling liquor is prepared through a cold-soaking method. The abdomen stasis-expelling liquor mainly aims to dysmenorrheal caused by cold coagulation and blood stasis. The abdomen stasis-expelling liquor is brewed from traditional Chinese medicines with the liquor so that effects of the traditional Chinese medicines can be achieved better. The abdomen stasis-expelling liquor can be used for a quite long time just through one brewing process without a step of decocting the drug every day. The abdomen stasis-expelling liquor is convenient, is quick in effect and is low in cost.
The present invention relates to a calcium alginate/poly arginine-chitin glycan composite medicine release-controlled microcapsule and a preparing method thereof. The microcapsule can be a bicomponent single-layer compound microcapsule film or a bicomponent double-layer compound microcapsule film. An electrostatic combined method is used to prepare the microcapsule, and meanwhile, the poly arginine and the chitin glycan are used as film forming materials for the preparation of the calcium alginate/poly arginine-chitin glycan composite medicine release-controlled microcapsule. A film is formed by using the poly arginine and the chitin glycan with the aid of a high-pressure electrostatic liquid drop generating device through the gelation of the outside of calcium alginate, sodium alginate is then used for surface modification, and thus, the calcium alginate/poly arginine-chitin glycan composite medicine release-controlled microcapsule having uniform and controllable particle diameter within a range of 200 to 1000 mu m and glabrous surface can be prepared. Therefore, the microcapsule not only can overcome the defects of film formation by using a single substance, but also can increase a nutritive function and a pharmacology effect of products to make the products have an interventional therapy function. The microcapsule can be widely used for embedding medicine or cells, and can be used in the field of medicine and biological engineering.
The invention relates to a preparation method and application of penicillium citrinum-derived penicitrinine A. The compound has the effect of restraining human nasopharyngeal carcinoma cell proliferation. The structural formula of the compound is shown in the description. According to the invention, through fermenting culture of penicillium citrinum IBPT-5, a fermentation product is obtained, and then the compound is separated and purified from the fermentation product. Experiment results confirm that the compound has better antitumor activity on human nasopharyngeal carcinoma cells such as CNE-1 and CNE-2. The penicillium citrinum-derived penicitrinine A can be applied to preparation of human nasopharyngeal carcinoma cell proliferation inhibition drugs or antitumor drugs to be used for research on human nasopharyngeal carcinoma.
Canonical transient receptor potential channel 3 (TRPC3) is the most abundant TRPC channel in the brain and is highly expressed in all subfields of the hippocampus. Previous studies have suggested that TRPC3 channels may be involved in the hyperexcitability of hippocampal pyramidal neurons and seizures. Genetic ablation of TRPC3 channel expression reduced the intensity of pilocarpine-induced status epilepticus (SE). However, the underlying cellular mechanisms remain unexplored and the contribution of TRPC3 channels to SE-induced neurodegeneration is not determined. In this study, we investigated the contribution of TRPC3 channels to the electrophysiological properties of hippocampal pyramidal neurons and hippocampal synaptic plasticity, and the contribution of TRPC3 channels to seizure-induced neuronal cell death. We found that genetic ablation of TRPC3 expression did not alter basic electrophysiological properties of hippocampal pyramidal neurons and had a complex impact on epileptiform bursting in CA3. However, TRPC3 channels contribute significantly to long-term potentiation in CA1 and SE-induced neurodegeneration. Our results provided further support for therapeutic potential of TRPC3 inhibitors and raised new questions that need to be answered by future studies.
JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with PD-(L)1i-experienced HNSCC.